Literature DB >> 23929766

Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions.

Harry K W Kim1, Gen-Sheng Feng, Di Chen, Philip D King, Nobuhiro Kamiya.   

Abstract

Metachondromatosis is a benign bone disease predominantly observed in the hands and feet of children or young adults demonstrating two different manifestations: a cartilage-capped bony outgrowth on the surface of the bone called exostosis and ectopic cartilaginous nodules inside the bone called enchondroma. Recently, it has been reported that loss-of-function mutations of the SHP2 gene, which encodes the SHP2 protein tyrosine phosphatase, are associated with metachondromatosis. The purpose of this study was to investigate the role of SHP2 in postnatal cartilage development, which is largely unknown. We disrupted Shp2 during the postnatal stage of mouse development in a chondrocyte-specific manner using a tamoxifen-inducible system. We found tumor-like nodules on the hands and feet within a month after the initial induction. The SHP2-deficient mice demonstrated an exostosis-like and enchondroma-like phenotype in multiple bones of the hands, feet, and ribs as assessed by X-ray and micro-computed tomography (CT). Histological assessment revealed the disorganization of the growth plate cartilage, a cartilaginous protrusion from the epiphyseal bone, and ectopic cartilage nodules within the bones, which is consistent with the pathological features of metachondromatosis in humans (ie, both exostosis and enchondroma). At molecular levels, we observed an abundant expression of Indian hedgehog protein (IHH) and fibroblast growth factor 2 (FGF2) and impaired expression of mitogen-activated protein kinases (MAPK) in the affected cartilage nodules in the SHP2-deficient mice. In summary, we have generated a mouse model of metachondromatosis that includes manifestations of exostosis and enchondroma. This study provides a novel model for the investigation of the pathophysiology of the disease and advances the understanding of metachondromatosis. This model will be useful to identify molecular mechanisms for the disease cause and progression as well as to develop new therapeutic strategies in the future.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CARTILAGE-SPECIFIC KNOCK-OUT MOUSE; ENCHONDROMA; EXOSTOSIS; METACHONDROMATOSIS; SHP2

Mesh:

Year:  2014        PMID: 23929766      PMCID: PMC4081537          DOI: 10.1002/jbmr.2062

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  31 in total

1.  A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.

Authors:  Kazu Matsumoto; Fumitoshi Irie; Susan Mackem; Yu Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  The role of Shp2 (PTPN11) in cancer.

Authors:  M Golam Mohi; Benjamin G Neel
Journal:  Curr Opin Genet Dev       Date:  2007-01-16       Impact factor: 5.578

Review 3.  The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.

Authors:  Marie Dance; Alexandra Montagner; Jean-Pierre Salles; Armelle Yart; Patrick Raynal
Journal:  Cell Signal       Date:  2007-10-11       Impact factor: 4.315

4.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

Review 5.  Noonan syndrome and related disorders: genetics and pathogenesis.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

6.  BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.

Authors:  Nobuhiro Kamiya; Ling Ye; Tatsuya Kobayashi; Yoshiyuki Mochida; Mitsuo Yamauchi; Henry M Kronenberg; Jian Q Feng; Yuji Mishina
Journal:  Development       Date:  2008-10-16       Impact factor: 6.868

7.  Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.

Authors:  Nobuhiro Kamiya; Ling Ye; Tatsuya Kobayashi; Donald J Lucas; Yoshiyuki Mochida; Mitsuo Yamauchi; Henry M Kronenberg; Jian Q Feng; Yuji Mishina
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

Review 8.  The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.

Authors:  Yoko Aoki; Tetsuya Niihori; Yoko Narumi; Shigeo Kure; Yoichi Matsubara
Journal:  Hum Mutat       Date:  2008-08       Impact factor: 4.878

Review 9.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

10.  Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.

Authors:  Nobuhiro Kamiya; Tatsuya Kobayashi; Yoshiyuki Mochida; Paul B Yu; Mitsuo Yamauchi; Henry M Kronenberg; Yuji Mishina
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

View more
  16 in total

1.  Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.

Authors:  Mylène Tajan; Julie Pernin-Grandjean; Nicolas Beton; Isabelle Gennero; Florence Capilla; Benjamin G Neel; Toshiyuki Araki; Philippe Valet; Maithé Tauber; Jean-Pierre Salles; Armelle Yart; Thomas Edouard
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

Review 2.  Hereditary Multiple Exostoses: a review of clinical appearance and metabolic pattern.

Authors:  Giovanni Beltrami; Gabriele Ristori; Guido Scoccianti; Angela Tamburini; Rodolfo Capanna
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

Review 3.  Col2CreER(T2), a mouse model for a chondrocyte-specific and inducible gene deletion.

Authors:  M Chen; S Li; W Xie; B Wang; D Chen
Journal:  Eur Cell Mater       Date:  2014-10-23       Impact factor: 3.942

4.  ERK1 and ERK2 regulate chondrocyte terminal differentiation during endochondral bone formation.

Authors:  Zhijun Chen; Susan X Yue; Guang Zhou; Edward M Greenfield; Shunichi Murakami
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

5.  NFAT restricts osteochondroma formation from entheseal progenitors.

Authors:  Xianpeng Ge; Kelly Tsang; Lizhi He; Roberto A Garcia; Joerg Ermann; Fumitaka Mizoguchi; Minjie Zhang; Bin Zhou; Bin Zhou; Antonios O Aliprantis
Journal:  JCI Insight       Date:  2016-04

6.  Germline Saturation Mutagenesis Induces Skeletal Phenotypes in Mice.

Authors:  Jonathan J Rios; Bruce Beutler; Kristin Denton; Jamie Russell; Julia Kozlitina; Carlos R Ferreira; Amy F Lewanda; Joshua E Mayfield; Eva Moresco; Sara Ludwig; Miao Tang; Xiaohong Li; Stephen Lyon; Anas Khanshour; Nandina Paria; Aysha Khalid; Yang Li; Xudong Xie; Jian Q Feng; Qian Xu; Yongbo Lu; Robert E Hammer; Carol A Wise
Journal:  J Bone Miner Res       Date:  2021-05-10       Impact factor: 6.390

7.  FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling.

Authors:  Siru Zhou; Yangli Xie; Junzhou Tang; Junlan Huang; Qizhao Huang; Wei Xu; Zuqiang Wang; Fengtao Luo; Quan Wang; Hangang Chen; Xiaolan Du; Yue Shen; Di Chen; Lin Chen
Journal:  PLoS Genet       Date:  2015-06-19       Impact factor: 5.917

8.  Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice.

Authors:  Philip E Lapinski; Melissa F Meyer; Gen-Sheng Feng; Nobuhiro Kamiya; Philip D King
Journal:  Dis Model Mech       Date:  2013-09-25       Impact factor: 5.758

9.  SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.

Authors:  Margot E Bowen; Ugur M Ayturk; Kyle C Kurek; Wentian Yang; Matthew L Warman
Journal:  PLoS Genet       Date:  2014-05-29       Impact factor: 5.917

10.  Conditional Deletion of Fgfr3 in Chondrocytes leads to Osteoarthritis-like Defects in Temporomandibular Joint of Adult Mice.

Authors:  Siru Zhou; Yangli Xie; Wei Li; Junlan Huang; Zuqiang Wang; Junzhou Tang; Wei Xu; Xianding Sun; Qiaoyan Tan; Shuo Huang; Fengtao Luo; Meng Xu; Jun Wang; Tingting Wu; Liang Chen; Hangang Chen; Nan Su; Xiaolan Du; Yue Shen; Lin Chen
Journal:  Sci Rep       Date:  2016-04-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.